Search

Your search keyword '"Soga, Yoshimitsu"' showing total 1,121 results
Start Over Author "Soga, Yoshimitsu"
1,121 results on '"Soga, Yoshimitsu"'

2. Twenty-Four-Month Safety and Effectiveness of TCD-17187 Drug-Coated Balloon for Treatment of Atherosclerotic Lesions in Superficial Femoral and Proximal Popliteal Artery

Author

Soga, Yoshimitsu, Iida, Osamu, Seki, Shu-Ichi, Kawasaki, Daizo, Anzai, Hitoshi, Ando, Hiroshi, Nakama, Tatsuya, Shinozaki, Norihiko, Kozuki, Amane, Ishihara, Masaharu, Urasawa, Kazushi, Toi, Satoru, Tsujita, Hiroaki, Tobita, Kazuki, Ogata, Kenji, Horie, Kazunori, Hayakawa, Naoki, Mori, Shinsuke, Fujihara, Masahiko, Ohki, Takao, Yuba, Kenichiro, Mano, Toshiaki, Ando, Kenji, and Nakamura, Masato

Published
2024
Full Text
View/download PDF

3. Editor's Choice – Impact of Infrapopliteal Revascularisation Establishing In Line Flow to the Wound in Patients with Chronic Limb Threatening Ischaemia

Author

Iida, Osamu, Takahara, Mitsuyoshi, Ohura, Norihiko, Hata, Yosuke, Kodama, Akio, Soga, Yoshimitsu, Yamaoka, Terutoshi, Urasawa, Kazushi, Sasaki, Shinya, Ando, Hiroshi, Yamauchi, Yasutaka, Kobayashi, Norihiro, Kato, Tamon, Tsubakimoto, Yoshinori, Kozuki, Amane, Kawasaki, Daizo, Seki, Shuichi, Suzuki, Kenji, Fujimura, Naoki, Fujihara, Masahiko, Uchida, Hisashi, Deguchi, Juno, Sugimoto, Masayuki, Komai, Hiroyoshi, Yunoki, Yasuhiro, Ohmine, Takahiro, Guntani, Atsushi, Morisaki, Koichi, Arata, Kenichi, Arai, Kiyohito, Nanto, Shinsuke, Yokoi, Hiroyoshi, Higuchi, Yoshiharu, and Azuma, Nobuyoshi

Published
2024
Full Text
View/download PDF

6. Mitral regurgitation is associated with similar loss of von Willebrand factor large multimers but lower frequency of anemia compared with aortic stenosis

Author

Takiguchi, Hiroshi, Miura, Mizuki, Shirai, Shin-ichi, Soga, Yoshimitsu, Hanyu, Michiya, Sakaguchi, Genichi, Soga, Yoshiharu, Arai, Yoshio, Watanabe, Shin, Kimura, Takeshi, Takahama, Hiroyuki, Yasuda, Satoshi, Nakayoshi, Takaharu, Fukumoto, Yoshihiro, Yaoita, Nobuhiro, Shimokawa, Hiroaki, Sakatsume, Ko, Saiki, Yoshikatsu, Kaikita, Koichi, Tsujita, Kenichi, Tamura, Toshihiro, Doman, Tsuyoshi, Yamashita, Mihoko, Suzuki, Misako, Eura, Yuka, Kokame, Koichi, Hayakawa, Masaki, Matsumoto, Masanori, Okubo, Noriyuki, Sugawara, Shingo, Fujimaki, Shin-ichi, Kawate, Yasunori, Ando, Kenji, and Horiuchi, Hisanori

Published
2024
Full Text
View/download PDF

8. von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis

Author

Okubo, Noriyuki, Sugawara, Shingo, Fujiwara, Tohru, Sakatsume, Ko, Doman, Tsuyoshi, Yamashita, Mihoko, Goto, Kota, Tateishi, Masaki, Suzuki, Misako, Shirakawa, Ryutaro, Eura, Yuka, Kokame, Koichi, Hayakawa, Masaki, Matsumoto, Masanori, Kawate, Yasunori, Miura, Mizuki, Takiguchi, Hiroshi, Soga, Yoshimitsu, Shirai, Shinichi, Ando, Kenji, Arai, Yoshio, Nakayoshi, Takaharu, Fukumoto, Yoshihiro, Takahama, Hiroyuki, Yasuda, Satoshi, Tamura, Toshihiro, Watanabe, Shin, Kimura, Takeshi, Yaoita, Nobuhiro, Shimokawa, Hiroaki, Saiki, Yoshikatsu, Kaikita, Koichi, Tsujita, Kenichi, Yoshii, Shinji, Nakase, Hiroshi, Fujimaki, Shin-ichi, and Horiuchi, Hisanori

Published
2024
Full Text
View/download PDF

15. Independent Predictors of Major Adverse Cardiovascular Events at 3 Years after Aortoiliac Stent Implantation

Author

Zen, Kan, Kozuki, Amane, Tsubakimoto, Yoshinori, Doijiri, Tatsuki, Utsunomiya, Makoto, Sasaki, Shinya, Anzai, Hitoshi, Ando, Hiroshi, Ohta, Hiroshi, Seki, Shuichi, Horimatsu, Tetsuo, Tanaka, Akiko, Nakamura, Hiroaki, Tanaka, Tomofumi, Horiguchi, Masahide, Nagase, Kimiaki, Takiuchi, Shin, Mizuno, Atsushi, Nakao, Masashi, Aihara, Hideaki, Nakahama, Makoto, Takahashi, Hiroki, Kaneko, Nobuhito, Mizuno, Sumio, Miyazawa, Tsuyoshi, Doi, Masayuki, Yoshioka, Ryo, Nakama, Tatsuya, Imoto, Hiroki, Urasawa, Kazushi, Okabayashi, Hiroaki, Suzuki, Hiroshi, Wake, Minoru, Niizeki, Takeshi, Kongoji, Ken, Tosaka, Jun, Matsuno, Shunsuke, Tanabe, Jun, Kawamoto, Kenji, Suzuki, Takahide, Iwata, You, Miura, Takashi, Suzuki, Yoriyasu, Tsuchiya, Takeshi, Munemasa, Mitsuru, Karashima, Eiji, Houzawa, Koji, Chiba, Yoshiro, Ito, Ryuta, Yamauchi, Yasutaka, Takahara, Mitsuyoshi, Iida, Osamu, Shintani, Yoshiaki, Sugano, Teruyasu, Yamamoto, Yoshito, Kawasaki, Daizo, Fujihara, Masahiko, Soga, Yoshimitsu, Hirano, Keisuke, Yamaguchi, Tetsuo, Yokoi, Hiroyoshi, Miyamoto, Akira, and Nakamura, Masato

Published
2022
Full Text
View/download PDF

17. Clinical validity of the Japanese below-the-knee chronic total occlusion scoring system for the prediction of successful guidewire crossing.

Author

Tan, Michinao, Ueshima, Daisuke, Iida, Osamu, Soga, Yoshimitsu, Tobita, Kazuki, Hayakawa, Naoki, Fujihara, Masahiko, Mori, Shinsuke, Tsubakimoto, Yoshinori, Nakao, Sho, Tokuda, Takahiro, Horie, Kazunori, Kato, Taku, Kaneko, Nobuhito, Ando, Hiroshi, Iwata, Shuko, Nakagawa, Yuya, Sunaga, Daisuke, and Urasawa, Kazushi

Abstract

To validate the Japanese below-the-knee (J-BTK) chronic total occlusion (CTO) score for the prediction of successful guidewire crossing (S-GC) in angiographic evaluation. A prospective, multicenter, nonrandomized study examined 751 consecutive BTK CTOs in 497 patients treated with endovascular therapy in 16 Japanese medical centers from April 2021 to March 2022. The cohort was classified into 2 groups: an S-GC group and a failed guidewire crossing group. The J-BTK CTO score, which assigned one point to "Blunt type at the proximal entry point," one point to "Calcification at the proximal entry point," one point to "Reference vessel diameter <2.0 mm," one point to "CTO length ≥200 mm," and two points to "No outflow of the target vessel," was used to categorize BTK CTOs into 4 grades with varying probabilities of S-GC: grade A (J-BTK CTO score of 0 and 1), grade B (score of 2 and 3), grade C (score of 4 and 5), and grade D (score of 6). Rates of S-GC in each grade (grades A, B, C, and D) were 97.5%, 89.1%, 62.5%, and 27.3%, respectively. The area under the receiver-operating characteristic curve for S-GC was 0.8304. Although the previous J-BTK CTO study enrolled only de novo lesions, both de novo and restenotic lesions were evaluated in this study. De novo lesions have a lower chance of S-GC (odds ratio: 0.24, 95% confidence interval: 0.09-0.67) in the multivariate analysis, and the area under the receiver-operating characteristic curve of the modified J-BTK CTO score, which additionally assigned two points to "De novo lesion," was 0.846. The modified J-BTK CTO score showed an appropriate calibration (Hosmer-Lemeshow P =.957). The J-BTK CTO score and the modified J-BTK CTO score predict the probability of an S-GC of BTK CTOs and stratify the difficulty of endovascular therapy for BTK CTOs in angiographic evaluation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Institutional Volume and Initial Results for Endovascular Treatment for Chronic Occlusive Lower-Extremity Artery Disease: A Report From the Japanese Nationwide Registry.

Author

Tokuda, Takahiro, Takahara, Mitsuyoshi, Iida, Osamu, Kohsaka, Shun, Soga, Yoshimitsu, Oba, Yasuhiro, Hirano, Keisuke, Shinke, Toshiro, Amano, Tetsuya, and Ikari, Yuji

Abstract

Purpose: Chronic total occlusion (CTO) remains as a major target for endovascular treatment (EVT) in improving symptomatic lower-extremity artery disease (LEAD). However, despite the technical demand and learning curve for the procedure, volume-outcome relationship of EVT targeted for CTO in symptomatic LEAD remains unclear. Materials and Methods: Data were obtained from a nationwide registry for EVT procedures limited to the Japanese Association of Cardiovascular Intervention and Therapeutics between January 2018 and December 2020 from 660 cardiovascular centers in Japan. In total, 96 099 patients underwent EVT for symptomatic LEAD, and 41 900 (43.6%) underwent CTO-targeted EVTs during the study period. Institutional volume was classified into quartiles. The association of institutional volumes with short-term outcomes was explored using the generalized linear mixed model using a logit link function, in which, interinstitution variability was used as a random effect. Results: The median institutional volume for all EVT cases per quartile was 29, 68, 125, and 299 cases/year for the first, second, third, and fourth quartiles, respectively. With each model analysis, the adjusted odds ratios (ORs) for technical success were significantly lower in patients who underwent EVT in institutions within the first quartile (<52 cases/year) than in the other quartiles (P <.01, respectively). On the contrary, the adjusted ORs for procedural complications were significantly higher in the first and second quartiles than in the third and fourth quartiles (P <.01, respectively). Conclusion: In contemporary Japanese EVT practice, a higher institutional volume but not operator volume was associated with a higher technical success rate and a lower procedural complication rate in patients with symptomatic LEAD involving CTO lesions. Clinical Impact: EVT for CTO lesions is still challenging for clinicians because of difficulties of wire/devise crossing or high procedural complications rate. Our study demonstrated that a higher institutional volume but not operator volume was associated with a higher technical success rate and a lower procedural complication rate in patients with symptomatic LEAD involving CTO lesions. In contemporary Japanese practice, a higher institutional experience has better impacts on short-term clinical outcomes. Future research should determine the relationship between institutional volume and long-term clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value

Author

Gray, William A, primary, Soga, Yoshimitsu, additional, Fujihara, Masahiko, additional, Iida, Osamu, additional, Babaev, Anvar, additional, Kawasaki, Daizo, additional, Zeller, Thomas, additional, O'Connor, David, additional, Jaff, Michael R, additional, Chavez, Anna M, additional, and Müller-Hülsbeck, Stefan, additional

Published
2024
Full Text
View/download PDF

29. Polymer-Based Drug-Eluting Stent Treatment Extends the Time to Reintervention for Patients With Symptomatic Femoropopliteal Artery Disease: Clinical Evidence and Potential Economic Value

Author

Gray, William, Soga, Yoshimitsu, Fujihara, Masahiko, Iida, Osamu, Babaev, Anvar, Kawasaki, Daizo, Zeller, Thomas, O'Connor, David, Jaff, Michael, Chavez, Anna, Müller-Hülsbeck, Stefan, Gray, William, Soga, Yoshimitsu, Fujihara, Masahiko, Iida, Osamu, Babaev, Anvar, Kawasaki, Daizo, Zeller, Thomas, O'Connor, David, Jaff, Michael, Chavez, Anna, and Müller-Hülsbeck, Stefan

Abstract

Aim: Use long-term follow-up data from the IMPERIAL study to determine whether drug-eluting polymer-based nitinol stent treatment can delay the time to repeat intervention for femoropopliteal artery disease and how such a delay may result in cost savings in a value-based episode of care. Patients & methods: The IMPERIAL randomized controlled trial was an international study of a paclitaxel-eluting polymer-coated stent (Eluvia, Boston Scientific, MA, USA) versus a polymer-free paclitaxel-coated stent (Zilver PTX, Cook Corporation, IN, USA) for treating lesions of the femoropopliteal arterial segment. Study patients (n = 465) had symptomatic lower limb ischemia. Safety and efficacy assessments were performed through 5 years. Mean time to first reintervention was calculated in post-hoc analysis for patients who underwent a clinically driven target lesion revascularization (CD-TLR) through 3 or 5 years following the index procedure. To simulate potential cost savings associated with differential CD-TLR burden over time, a cost-avoidance analysis using input parameters from IMPERIAL and US 100% Medicare standard analytical files was developed. Results: Among patients with a first CD-TLR through 3 years of follow-up, mean time to reintervention was 5.5 months longer (difference 166 days, 95% CI: 51, 282 days; p = 0.0058) for patients treated with Eluvia (n = 56) than for those treated with Zilver PTX (n = 30). Through the 5-year study follow-up period, CD-TLR rates were 29.3% (68/232) for Eluvia and 34.2% (39/114) for Zilver PTX (p = 0.3540) and mean time to first reintervention exceeded 2 years for patients treated with Eluvia at 737 days versus 645 days for the Zilver PTX group (difference 92 days, 95% CI: -85, 269 days; p = 0.3099). Simulated savings considering reinterventions occurring over 1 and 5 years following initial use of Eluvia over Zilver PTX were US $1,395,635 and US $1,531,795, respectively, when IMPERIAL CD-TLR rates were extrapolated to 1000 patients. Co

Published
2024

31. Five-year outcomes of the GORE VIABAHN Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study.

Author

Iida, Osamu, Ohki, Takao, Soga, Yoshimitsu, Suematsu, Nobuhiro, Nakama, Tatsuya, Yamaoka, Terutoshi, Tobita, Kazuki, and Ichihashi, Shigeo

Subjects
PERIPHERAL vascular diseases, CHRONIC total occlusion, ENDOVASCULAR surgery, JAPANESE people, TREATMENT effectiveness, ANKLE brachial index
Abstract

Introduction: The safety and effectiveness of the GORE VIABAHN Endoprosthesis for treatment of symptomatic patients with peripheral artery disease (PAD) and complex femoropopliteal (FP) lesions was assessed in a real-world Japanese practice setting. Methods : A prospective, multicenter, postmarket surveillance study was conducted from 2016 to 2017 at 64 sites in Japan. Symptomatic patients with PAD and FP lesions ⩾ 10 cm and reference vessel diameters ranging from 4.0 to 7.5 mm were eligible for enrollment. Outcome measures evaluated at 5 years were primary patency (PP), primary-assisted patency (PAP), secondary patency (SP), freedom from target lesion revascularization (fTLR), occurrence of device- or procedure-related serious adverse events (SAEs), and stent fractures. Results : A total of 321 patients were enrolled and were a mean age of 73.9 ± 8.7 years; 77.3% were men and 26.5% had chronic limb-threatening ischemia (CLTI). The mean lesion length was 23.6 ± 6.6 cm and the frequency with TASC II C/D lesions and chronic total occlusions was 86.6% and 70.4%, respectively. The Kaplan–Meier estimated PP, PAP, SP, and fTLR at 5 years was 62.4%, 74.1%, 82.3%, and 75.9%, respectively. The mean ankle–brachial index was 0.92 ± 0.15 and the mean improvement in Rutherford class was 2.3 ± 1.4, which was maintained through 5 years. The rate of cumulative device- or procedure-related SAEs through 5 years was 19.9% with only 9.3% of those occurring after the first year. No stent fractures were observed through 5 years by x-ray evaluation. Conclusion : The 5-year safety and efficacy outcomes of the endoprosthesis were clinically acceptable for treating complex FP lesions in a real-world cohort of Japanese patients with PAD. (ClinicalTrials.gov Identifier: NCT04706273) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization.

Author

Takahara, Mitsuyoshi, Soga, Yoshimitsu, and Iida, Osamu

Subjects
CORONARY artery disease, ARTERIAL diseases, MORTALITY, POISSON regression
Abstract

Background and Aims Patients undergoing revascularization for lower extremity arterial disease (LEAD) may face a higher risk of mortality than those with coronary artery disease (CAD). This study aimed to characterize the difference in mortality risk between patients undergoing revascularization for LEAD and CAD and identify associated factors. Methods The 1-year database of 10 754 patients undergoing revascularization for CAD (n = 6349) and LEAD (n = 4405) was analysed. Poisson regression models were used to characterize interpopulation differences in mortality, adjusting for baseline clinical features, including age, sex, polyvascular disease, comorbidities, medications, and vulnerabilities. Results Individuals with LEAD were older, were more likely to have polyvascular disease, had more comorbidities, and received fewer cardioprotective drugs than those with CAD. Vulnerabilities remained more common in the LEAD group even after adjusting for these clinical features. The crude risk ratio of mortality incidence for LEAD vs. CAD was 2.91 (95% confidence interval, 2.54–3.34), attenuated to 2.14 (1.83–2.50) after controlling for age, sex, and polyvascular disease. The percentage attenuation in the excessive mortality associated with LEAD was 29%. The stepwise addition of comorbidities, medications, and vulnerabilities as adjusting factors attenuated the incidence risk ratio to 1.48 (1.26–1.72), 1.33 (1.12–1.58), and 1.17 (0.98–1.39), respectively, and increased the percentage attenuation to 64%, 73%, and 86%, respectively. Conclusions Mortality risk was almost three-fold higher in patients undergoing revascularization for LEAD than in those with CAD. The excessive mortality was considerably attributable to inter-group differences in baseline characteristics, including potentially clinically or socially modifiable factors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Three-year clinical course after fluoropolymer-based drug-eluting stent implantation for femoropopliteal lesions.

Author

Iida, Osamu, Takahara, Mitsuyoshi, Soga, Yoshimitsu, Yamaoka, Terutoshi, Fujihara, Masahiko, Kawasaki, Daizo, Ichihashi, Shigeo, Sakata, Yasushi, Mano, Toshiaki, and Higuchi, Yoshiharu

Subjects
CHRONIC total occlusion, PERIPHERAL vascular diseases, THROMBOSIS, CHRONIC wounds & injuries
Abstract

Background: Although the 1-year clinical outcomes of fluoropolymer-based drug-eluting stents (FP-DES) were favorable for the treatment of real-world femoropopliteal lesions in symptomatic peripheral artery disease (PAD), their performance beyond 1 year remained unknown. The current study determined the 3-year clinical course of FP-DES implantation for real-world femoropopliteal lesions. Methods: This multicenter, prospective, observational study evaluated 1204 limbs (chronic limb-threatening ischemia, 34.8%; mean lesion length, 18.6 ± 9.9 cm, chronic total occlusion: 53.2%) of 1097 patients with PAD (age, 75 ± 9 years; diabetes mellitus, 60.8%) undergoing FP-DES implantation for femoropopliteal lesions. The primary outcome measure was 3-year restenosis. The secondary outcome measures included 3-year occlusive restenosis, stent thrombosis, target lesion revascularization (TLR), and aneurysmal degeneration. Results: The 3-year cumulative occurrence of restenosis was 27.3%, whereas that of occlusive restenosis, stent thrombosis, and TLR was 16.1%, 7.3%, and 19.6%, respectively. The annual occurrence of restenosis decreased by 12.0%, 9.5%, and 5.8% in the first, second, and third year, respectively (p < 0.001). Similarly, the rates of occlusive restenosis and stent thrombosis decreased (p < 0.001 and p = 0.007, respectively), whereas the rate of TLR remained unchanged for 3 years (p = 0.15). The incidence of aneurysmal degeneration at 3 years (15.7%) did not significantly differ from that at 1 and 2 years (p = 0.69 and 0.20, respectively). Conclusions: This study highlights the favorable long-term clinical course of FP-DES in real-world practice, emphasizing the importance of monitoring for occlusive restenosis and stent thrombosis while considering the potential onset of aneurysmal degeneration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Primary results of the SAVAL randomized trial of a paclitaxel-eluting nitinol stent versus percutaneous transluminal angioplasty in infrapopliteal arteries

Author

van Overhagen, Hans, primary, Nakamura, Masato, additional, Geraghty, Patrick J, additional, Rao, Sid, additional, Arroyo, Max, additional, Soga, Yoshimitsu, additional, Iida, Osamu, additional, Armstrong, Ehrin, additional, Nakama, Tatsuya, additional, Fujihara, Masahiko, additional, Ansari, Mohammad M, additional, Mathews, Santhosh J, additional, Gouëffic, Yann, additional, Jaff, Michael R, additional, Weinberg, Ido, additional, Pinto, Duane S, additional, Ohura, Norihiko, additional, Couch, Kara, additional, and Mustapha, Jihad A, additional

Published
2023
Full Text
View/download PDF

45. Clinical Impact of Additional Cilostazol Treatment on Restenosis Risk following Heparin-Bonded Stent Graft Implantation: Sub-Analysis from the Viabahn Stent-Graft Placement for Femoropopliteal Diseases Requiring Endovascular Therapy (VANQUISH) Study

Author

Tobita, Kazuki, primary, Takahara, Mitsuyoshi, additional, Iida, Osamu, additional, Soga, Yoshimitsu, additional, Yamaoka, Terutoshi, additional, Ichihashi, Shigeo, additional, and Saito, Shigeru, additional

Published
2023
Full Text
View/download PDF

46. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial

Author

Albrecht, Thomas, Ando, Kenji, Babaev, Anvar, Bacharach, Michael J, Bachinsky, William, Bajakian, Danielle, Beasley, Robert, Benenati, James, Benko, Andrew, Burket, Mark, Cardenas, Joseph, Das, Tony, De Martino, Randall, Deutschmann, Hannes, Dulas, Daniel, Feldman, Robert, Fugate, Mark, Garcia, Lawrence, Golzar, Jaafer, Gutta, Rao, Hall, Patrick, Hawkins, Stewart, Henao, Steve, Herdrich, Benjamin, Hirano, Keisuke, Holden, Andrew, Jaalouk, Safwan, Janzer, Sean, Kawasaki, Daizo, Keirse, Koen, Khatib, Yazan, Kichikawa, Kimihiko, Korngold, Ethan, Loewe, Christian, Lopez, Louis, Lui, Henry, Mano, Toshiaki, Mendes, Robert, Miyamoto, Akira, Müller-Hülsbeck, Stefan, Nakamura, Masato, O'Connor, David, Ohki, Takao, Park, James, Powell, Richard, Pratsos, Antonis, Prem, Jeffery, Rao, Vikram, Rashid, John, Rhee, Robert, Ricci, Jason, Scheinert, Dierk, Schroë, Herman, Schroeder, Henrik, Simon, Peter O, Jr., Singh, Gagan, Tan, Kongteng, Tolerico, Paul, Vasudevan, Thodur, Vermassen, Frank, Werner, Martin, Wiechmann, Bret, Yokoi, Hiroyoshi, Yokoi, Yoshiaki, Zeller, Thomas, Gray, William A, Soga, Yoshimitsu, Prem, Jeffery T, Popma, Jeffrey, Jaff, Michael R, and Diaz-Cartelle, Juan

Published
2018
Full Text
View/download PDF

48. Impact of postprocedural minimum lumen area on clinical outcome after femoropopliteal drug-eluting stent implantation

Author

Haraguchi, Takuya, primary, Takahara, Mitsuyoshi, additional, Iida, Osamu, additional, Soga, Yoshimitsu, additional, Yamaoka, Terutoshi, additional, Fujihara, Masahiko, additional, Kawasaki, Daizo, additional, Ichihashi, Shigeo, additional, Kozuki, Amane, additional, Sato, Katsuhiko, additional, and Fujita, Tsutomu, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results